证券代码：688046 证券简称：药康生物 编号：2022-001 投资者关系活动记录表 江苏集萃药康生物科技股份有限公司 | --- | --- | --- | |----------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者活动关系 | | ...

投资者关系活动记录表 证券代码：688046 证券简称：药康生物 编号：2022-003 江苏集萃药康生物科技股份有限公司 | --- | --- | --- | |-----------------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | 投资者活动关系 | | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：688046 证券简称：药康生物 江苏集萃药康生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|-----------------------------------------|----------------|--------------------------- ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 20% increase compared to the same period last year[2]. - The company reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - The company achieved total revenue of 250.37 million yuan, a year-on-year increase of 40.29%, and a net profit attributable to shareholders of 81.64 million yuan, up 76.16% year-on-year[129]. - The company reported a total revenue of 53,400 million RMB, with a net profit of 3,861.08 million RMB for the first half of 2022[119]. - The gross margin improved to 45%, up from 40% in the same period last year, reflecting better cost management and pricing strategies[19]. - The net profit attributable to shareholders was ¥81,635,012.80, a 76.16% increase from ¥46,341,369.79 year-on-year[32]. - The net cash flow from operating activities increased by 111.37% to ¥22,135,482.77, up from ¥10,472,319.95 in the previous year[32]. - The company's total assets grew to ¥2,176,019,760.00, a 106.37% increase from ¥1,054,409,220.49 at the end of the previous year[32]. - The company's cash flow from operating activities increased by 111.37% to CNY 22.14 million[154]. - The company recognized government subsidies of CNY 25.68 million, accounting for 27.52% of the total profit for the reporting period[151]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching 1.2 million users by the end of June 2022[2]. - User data showed an increase in active users by 20% compared to the previous year, reaching 5 million active users[19]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[19]. - The overseas market generated revenue of 24.87 million yuan, accounting for 9.93% of total revenue, with a year-on-year growth of 98.40%[130]. Research and Development - Investment in R&D increased by 25% year-on-year, focusing on new technologies and product development[19]. - The R&D expenditure as a percentage of revenue increased to 15.42%, up from 13.26% year-on-year, indicating a focus on innovation[35]. - The company achieved a total R&D investment of ¥38,610,778.49, representing a year-on-year increase of 63.17%[106]. - The company published a total of 1,071 SCI articles with a cumulative impact factor of 9,978.5, including 390 articles published during the reporting period with an impact factor of 3,511.9[103]. - The company has developed over 20,000 proprietary commercial mouse models, maintaining a leading position in the industry[124]. - The company is currently undertaking four major scientific research projects, including the National Genetic Engineering Mouse Resource Bank and gene-modified animal models for cardiovascular and metabolic diseases[100]. Product Development and Innovation - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials by Q4 2022[2]. - The company is set to launch two new products in Q4 2022, anticipated to contribute an additional RMB 300 million in revenue[19]. - The company has created an innovative drug screening and phenotypic analysis platform, providing comprehensive in vivo and in vitro evaluation services for drug efficacy and mechanisms[47]. - The company has developed several innovative models, including NCG-IL15 and K18-hACE2, leading the industry in model creation capabilities and product quality[76]. - The company is advancing its new generation model development, including "Drug Screening Mice" and "Germ-Free Mice," positioning itself as a leader in the industry[125]. Strategic Acquisitions and Partnerships - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 50 million RMB in revenue annually[2]. - A strategic acquisition of a smaller biotech firm was announced, expected to enhance the company's product pipeline and innovation capabilities[19]. - A new partnership with a leading research institution was established to accelerate the development of next-generation therapies[19]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[5]. - The company faces risks related to the uncertainty of CRISPR/Cas9 technology licensing and potential increases in costs if alternative technologies are required[145]. Environmental and Compliance Practices - The company has maintained a good environmental compliance record with no administrative penalties for environmental issues during the reporting period[175]. - The company employs active carbon adsorption and deodorization devices to treat exhaust gases, ensuring emissions meet standards[177]. - The company promotes sustainable development by advocating for green office practices and resource conservation among employees[178]. - The company has implemented a comprehensive environmental management system in accordance with national regulations[175]. Shareholding and Governance - The company has committed to various shareholding restrictions for major stakeholders, ensuring compliance with lock-up periods[183]. - The controlling shareholder will hold the company's shares long-term and will not reduce holdings within two years after the lock-up period[190]. - The company will ensure compliance with the Shanghai Stock Exchange's regulations on shareholder reductions and management[194]. - The company emphasizes strict adherence to the Securities Law and related regulations to ensure transparent and responsible shareholding practices[198].